- Breast conservation therapy (BCT) and mastectomy share similar OS in a large cohort of patients with T3 breast cancer (>5 cm).
Why this matters
- Tumor size >5 cm should not be exclusionary for BCT.
- Retrospective cohort (n=37,268) of patients with noninflammatory breast cancer >5 cm (2004-2011) in the National Cancer Database (NCDB) who underwent BCT (15%) or mastectomy (85%).
- Skin or chest wall involvement were excluded.
- Funding: US Public Health Service; Fox Chase Cancer Center Board of Associates.
- The BCT group had smaller tumor size (6.0 cm vs 6.7 cm in the mastectomy group; P<.001>
- Median follow-up was 51.4 months.
- The BCT group had similar OS as the mastectomy group (P=.357), with a 5-year adjusted OS of 68% vs 69%, respectively (P=.63).
- The largest predictors of BCT were administration of neoadjuvant chemotherapy (P<.001 grade iii tumors and black race>
- BCT receipt decreased from 17.5% in 2004 to 15% in 2011 (P<.001 despite no change in tumor size>trend=.22).
- Observational design.